Zacks Investment Research upgraded shares of COLLPLANT HOLDI/S (NASDAQ:CLGN) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $6.00 target price on the stock.

According to Zacks, “Collplant holdings Ltd is a regenerative medicine company focused on 3D bioprinting of tissues and organs. It involved in developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. It product pipeline include rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs, Vergenix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds. Collplant holdings Ltd is based in NESS-ZIONA, Israel. “

Separately, HC Wainwright initiated coverage on shares of COLLPLANT HOLDI/S in a report on Tuesday, December 18th. They issued a buy rating and a $7.00 target price on the stock.

CLGN stock opened at $5.37 on Wednesday. COLLPLANT HOLDI/S has a 12 month low of $3.13 and a 12 month high of $8.73. The stock has a market capitalization of $20.49 million, a price-to-earnings ratio of -9.75 and a beta of 2.32.

About COLLPLANT HOLDI/S

CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe.

Featured Story: Understanding Market Liquidity

Get a free copy of the Zacks research report on COLLPLANT HOLDI/S (CLGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for COLLPLANT HOLDI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COLLPLANT HOLDI/S and related companies with MarketBeat.com's FREE daily email newsletter.